MedWatch

Genmab CEO brushes off conflict with Janssen: "It's business as usual"

The royalty conflict with Janssen over the selling of the cancer drug Darzalex will have no financial repercussions for Genmab, according to CEO Jan van de Winkel. The biotech firm has too much tailwind for that to happen.

Genmab President & CEO Jan van de Winkel | Foto: Stine Bidstrup/ERH

It sent shock waves through the market in September, when Genmab informed it had gone on the offense against its years-long partner Janssen in a conflict revolving around the royalties of the blockbuster Darzalex.

The conflict arose in the wake of a newer and faster version of Darzalex called Darzalex Faspro, which exploits Halozyme technology, for which reason the latter will receive sales royalties. Janssen claims Genmab should participate in paying these royalties, for which reason the US firm has decided to withhold some of the royalty fees relating to Darzalex from Genmab. Genmab has challenged this decision, for which reason it will be going to trial.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Biontech-direktører: Derfor måtte Afrika vente på coronavacciner

Tyske Biontech vil bruge de mange corona-milliarder på at hjælpe lande i Afrika med at komme både coronavirus, malaria og turberkulose til livs, men alligevel stod kontinentet langt nede i køen, da de første coronavacciner skulle distribueres. MedWatch har spurgt hvorfor.

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier